Researchers in Australia Develop New Drugs to Prevent and Treat COVID-19

 

Professor Sudha Rao, senior researcher and head of QIMR Berghofer’s Gene Regulation and Translational Medicine Group, have developed two peptide-based drugs now being tested in hamsters at IDMIT, a pre-clinical and clinical research facility in France.

Research has been conducted in QIMR Berghofer Medical Research Institute in Brisbane, Australia regarding two drugs for the prevention spreading   COVID-19 with those that have been infected.

Professor Sudha Rao, senior researcher and head of QIMR Berghofer’s Gene Regulation and Translational Medicine Group, have developed two peptide-based drugs now being tested in hamsters at IDMIT, a pre-clinical and clinical research facility in France.

Results are promising. The drug is reported to have very few side effects and it is non-toxic.

Vaccines are slower because they rely on human body’s own immune system learning to mount immunity, Rao told Australian Associated Press (AAP). Rao also told AAP- “These are the first drugs we are aware of that can operate on dual fronts.

“We hope, if the clinical trials are successful, that the first drug could be given as a therapy alongside vaccination to prevent the virus binding to cells and taking hold, while the second peptide could be used to stop the virus replicating in already-infected patients.”

Could this be good for those who have not been vaccinated?

“Our drugs are a very rapid fix. So basically, if someone is exposed, if someone believes that they are exposed, then these drugs work very quickly to prevent the virus from replicating or entering,” Rao said. “What’s important here is that in this pandemic, COVID-19 is here to stay and we’re going to need multiple tools in our toolbox.”

The drugs could also be significant for people who haven’t been vaccinated or who are unable to get vaccinations due to allergies or illness.

These peptide-based drugs are aimed at preventing infection in the first place, and at reducing the severity of the disease before it really takes hold,” Seddiki said.

Source: qimrberghofer.edu.au


Follow us on Google news for more updates and News










PLEASE READ THE IMPORTANT DISCLOSURES BELOW.

This content is being provided to you for informational purposes only. The content has been prepared by third parties not affiliated with CWEB Inc, a business. This content and any information contained therein, does not constitute a recommendation by CWEB to buy, sell or hold any security, financial product or instrument referenced in the content. This information neither is, nor should be construed as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. CWEB Inc. does not offer or provide any opinion regarding the nature, potential, value, suitability or profitability of any particular investment or investment strategy, and you shall be fully responsible for any investment decisions you make, and such decisions will be based solely on your evaluation of your financial circumstances, investment objectives, risk tolerance, and liquidity needs.

Unless stated otherwise, the web content provided by the CWEB family of companies is for educational purposes only. The information and tools provided neither are, nor should be construed, as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. or its affiliates. Unless stated otherwise, no information presented constitutes a recommendation by CWEB Inc. or its affiliates to buy, sell or hold any security, financial product or instrument discussed therein or to engage in any specific investment strategy.

Full Disclaimer


>